Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study
作者:, ANRS CO12 CirVir Group
摘要:Background & Aims Semi-annual surveillance for hepatocellular carcinoma (HCC) is recommended for patients with cirrhosis. We aimed to determine how compliance with HCC surveillance guidelines affects survival times of patients with hepatitis C virus– or hepatitis B virus–associated compensated cirrhosis who developed HCC. Methods We collected data from the prospective ANRS CO12 CirVir study, from March 2006 through June 2012, on 1671 patients with biopsy-proven viral cirrhosis and no previous liver complications who were undergoing surveillance for HCC at 35 centers in France. Only 216 patients who developed HCC during the follow-up period were included in the analysis. Patients were considered to be compliant with surveillance guidelines if the time between their last surveillance image evaluation and diagnosis of HCC were fewer than 7 months and noncompliant if this time was 7 months or longer. Results HCC was detected in 216 patients, at a median follow-up time of 59.7 months. Of these patients, 140 (80.5%) were Barcelona Clinic Liver Cancer stage 0/A, 135 (69.9%) received first-line curative treatment (15 underwent transplantation, 29 underwent resection, 89 received percutaneous ablation, and 2 received resection and percutaneous ablation), and 129 (60.0%) were compliant with surveillance guidelines. Seventy-nine of the patients with HCC died; 49 deaths were associated with tumor progression. After lead-time adjustment, overall survival (OS) time was longer in patients compliant with surveillance guidelines (median OS time, 53.2 months) than noncompliant patients (median OS time, 25.4 months) (P = .0107); this difference remained significant even when we changed lead time assumptions. In multivariate analysis adjusted for a propensity score, compliance with HCC surveillance guidelines was associated with low tumor burden, allocation of curative treatment, and increased OS time compared with noncompliance (hazard ratio for OS, 2.19; 95% confidence interval, 1.16–4.14; P = .0150). Conclusions In an analysis of data from the ANRS CO12 CirVir cohort, we associated compliance with HCC surveillance guidelines (fewer than 7 months between image evaluations) with early diagnosis, allocation of curative treatment, and longer adjusted OS of patients with hepatitis C virus– or hepatitis B virus–associated compensated cirrhosis and a diagnosis of HCC.
关键词:
论文方向:[{"id":912,"name":"肿瘤学"}]
发表期刊:Gastroenterology Volume 155, Issue 2
发表时间:Fri Aug 31 00:00:00 CST 2018
数字识别码:10.1053/j.gastro.2018.04.027
是否作者本人: 否
版权及免责声明:
本网站所有论文文件均系用户自行上传或提供,本网站对其内容准确性及合法性概不负责,亦不承担任何法律责任。论文版权归原作者及原出处所有。
如您发现网站其他用户上传的论文有侵犯您的姓名权、隐私权、著作权或其他合法权益现象的,请及时与本网站联系并附加相关权利证明文件,以便本网站及时作出处理,维护您的合法权益。
本网站拥有对此声明的最终解释权。
{replyUser1} 回复 {replyUser2}:{content}